About Novacta

Novacta is seeking partners for further clinical development of NVB302, its anti-C.difficile antibiotic which has successfully completed a phase I clinical trial in healthy volunteers

 

 

Novacta's NVB333 for systemic treatment of Gram-positive infections together with its second generation polymyxin programme have been licensed and are under development in Cantab Anti-Infectives. (www.cantabanti.com)